Immune Activation Could Hold the Key to Success of Dual-Target CAR T Therapy in Glioblastoma
Recurrent glioblastoma (GBM), a notoriously aggressive and lethal brain cancer, continues to pose a formidable challenge for oncology, partly due ...
Recurrent glioblastoma (GBM), a notoriously aggressive and lethal brain cancer, continues to pose a formidable challenge for oncology, partly due ...
Philadelphia-based researchers from the Abramson Cancer Center at the University of Pennsylvania, alongside colleagues at Penn’s Perelman School of Medicine, ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine